FDA layoffs put drug and device review deadlines at risk
Reporting and findings
- reported
Reuters reported that FDA staff were struggling to meet drug and medical-device review deadlines after DOGE layoffs removed support and review personnel, creating approval uncertainty for patients and manufacturers.
- Reuters: FDA staff struggle to meet product review deadlines after DOGE layoffsPassages and source records documenting: FDA layoffs put drug and device review deadlines at risk
- documented
Robert F. Kennedy Jr. was the Trump-appointed health and human services secretary.
- U.S. Department of Health and Human Services: Robert F. Kennedy, Jr.Appointment or biography record identifying Robert F. Kennedy Jr. as Trump-appointed health and human services secretary
- documented
Elon Musk was the Trump-appointed senior adviser who led DOGE work.
- The White House: President Trump participates in a press conference with departing DOGE adviser Elon MuskAppointment or biography record identifying Elon Musk as Trump-appointed senior adviser who led DOGE work
Summary and current status
Delays create costs for patients awaiting products and firms financing development while regulatory clocks run.
FDA teams reported difficulty meeting statutory product-review deadlines
People and organizations
- Robert F. Kennedy Jr.Trump-appointed health and human services secretary
- Elon MuskTrump-appointed senior adviser who led DOGE work
- Donald J. Trumppresident authorizing the administration action
- Food and Drug Administrationregulator responsible for product-review deadlines
Relationships in this file
- Elon Muskcut staff needed to complete drug and device reviewsFood and Drug Administration
- Donald J. TrumpTrump-appointed health and human services secretaryRobert F. Kennedy Jr.
- Donald J. TrumpTrump-appointed senior adviser who led DOGE workElon Musk